These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26457446)

  • 21. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes.
    Schoos MM; Clemmensen P; Dangas GD
    JACC Cardiovasc Interv; 2014 May; 7(5):494-6. PubMed ID: 24852803
    [No Abstract]   [Full Text] [Related]  

  • 24. The clinical challenge of disappearing stents.
    Finn AV; Virmani R
    Lancet; 2016 Feb; 387(10018):510-512. PubMed ID: 26597772
    [No Abstract]   [Full Text] [Related]  

  • 25. Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience.
    Karanasos A; Van Mieghem N; van Ditzhuijzen N; Felix C; Daemen J; Autar A; Onuma Y; Kurata M; Diletti R; Valgimigli M; Kauer F; van Beusekom H; de Jaegere P; Zijlstra F; van Geuns RJ; Regar E
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25969547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging assessment of bioresorbable vascular scaffolds.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Collet C; Nakatani S; Okamura T; Muramatsu T; Ishibashi Y; Tateishi H; Miyazaki Y; Asano T; Katagiri Y; von Zur Muehlen C; Tanabe K; Kozuma K; Ozaki Y; Serruys PW; Onuma Y
    Cardiovasc Interv Ther; 2018 Jan; 33(1):11-22. PubMed ID: 28766253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial.
    de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J
    Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis.
    Campos CM; Garcia-Garcia HM; Muramatsu T; de Araujo Gonçalves P; Onuma Y; Dudek D; Thuesen L; Webster MW; Kitslaar P; Veldhof S; Reiber JH; Nieman K; Ormiston JA; Serruys PW
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):109-16. PubMed ID: 26739828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bifurcation stenting with bioresorbable scaffolds: Quo vadis?
    Kornowski R
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):863-864. PubMed ID: 27886456
    [No Abstract]   [Full Text] [Related]  

  • 32. Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience.
    Picard F; Marquis-Gravel G; Avram R; Ly HQ; Dorval JF; Doucet S; de Hemptinne Q; L'allier PL; Tanguay JF
    J Interv Cardiol; 2017 Oct; 30(5):433-439. PubMed ID: 28799238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions.
    Fam JM; Ishibashi Y; Felix C; Zhang BC; Diletti R; van Mieghem N; Regar E; van Domburg R; Onuma Y; van Geuns RJ
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1863-1871. PubMed ID: 28685314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball.
    Byrne RA; Kastrati A
    Eur Heart J; 2015 May; 36(20):1212-5. PubMed ID: 25784753
    [No Abstract]   [Full Text] [Related]  

  • 36. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
    Ali ZA; Serruys PW; Kimura T; Gao R; Ellis SG; Kereiakes DJ; Onuma Y; Simonton C; Zhang Z; Stone GW
    Lancet; 2017 Aug; 390(10096):760-772. PubMed ID: 28732815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optical coherence tomography imaging of everolimus-eluting bioresorbable vascular scaffold implanted into coronary vein graft at 3-month follow-up.
    Roleder T; Parma Z; Smolka G; Ochała A; Wojakowski W
    Eur Heart J; 2014 Sep; 35(33):2207. PubMed ID: 24722807
    [No Abstract]   [Full Text] [Related]  

  • 40. Coronary bifurcations: still the touchstone of drug-eluting stents and bioresorbable vascular scaffolds?
    von Birgelen C; van Houwelingen KG; Lam MK
    Rev Esp Cardiol (Engl Ed); 2014 Oct; 67(10):787-9. PubMed ID: 25262123
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.